ONO Pharmaceutical USA
Präsenz
ONO Pharmaceutical ist einer der ...
ONO Pharmaceutical ist ein Unternehmen, das unter dem Börsenticker 4528 (JP) gelistet ist.
ONO Pharmaceutical hat eine direkte Präsenz in 2 Ländern.
Führungskräfte
Siehe das Organigramm mit seine 3 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei ONO Pharmaceutical USA
- Kunihiko Ito, President and Chief Executive Officer
- David Trexler, Chief Commercial Officer
- Thomas Lechner, Vice President, Medical Affairs
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von ONO Pharmaceutical USA nachzuverfolgen.
Pharmazie
ONO Pharmaceutical hat 1.861 Konkurrenten , einschließlich Pfizer (USA), Sanofi (Frankreich) und Johnson & Johnson (USA).
Popular M&A news in Pharmazie
- MedMen has filed for bankruptcy protection (veröffentlicht am 28, April 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (veröffentlicht am 23, März 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (veröffentlicht am 19, März 2024).
Andere vorgeschlagene Kontakte der Pharmazie branche
Nachrichten
Neueste Pressemitteilungen nach ONO Pharmaceutical USA
- ONO PHARMA Announces Enrollment Is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL | ONO Pharma USA, Inc.
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University | ONO Pharma USA, Inc.
- Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins | ONO Pharma USA, Inc.
- ONO Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2023 | ONO Pharma USA, Inc.
- Support for Disasters Caused by the 2024 Noto Peninsula Earthquake | ONO Pharma USA, Inc.
- Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs | ONO Pharma USA, Inc.
- ONO Selected for the DJSI World Index and DJSI Asia Pacific Index for Four Straight Years | ONO Pharma USA, Inc.
- Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Ono Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- View more press releases Close
Social media about ONO Pharmaceutical USA
- ONO Pharmaceutical USA auf Wikipedia, Google News & Yahoo Finance
- ONO Pharmaceutical USA auf LinkedIn, Twitter & YouTube
